Intrinsiqq
Compugen Ltd. logo

Compugen Ltd. Intrinsic Value

CGEN

⊜ Compare

Choose a model

Each card values Compugen a different way, shown at our starting inputs. Pick one to see and change how it works.

Set your assumptions

Compugen on earnings: earnings per share grow for a few years, then the stock trades at a normal price-to-earnings multiple.

Years to project

Growth of earnings per share

Earnings per share; not enough history; starts at 5%

Exit P/E

Starts at its industry's median P/E

Your desired return

Margin of safety

More

Your buy price

The expected return is measured from it; starts at today's price

How it's worked out

  1. Today's earnings per share

    Diluted EPS of $0.38 as filed, last twelve months, lowered to what operating profit after tax supports (one-off gains left out)

    $0.29

  2. Earnings in 2031

    Grows 5.0% a year for 5 years

    $0.37

  3. Price in 2031

    $0.37 × 13.4 P/E

    $5.01

  4. Worth today

    ÷ 1.10^5: your 10% a year, taken back out

    $3.11

  5. Fair value

    The most you can pay and still earn 10% a year

    $3.11

  6. Buy below

    Fair value minus your 25% margin of safety

    $2.33

Paying $2.03 instead gives 19.8% a year. Every rule is on the methodology page.

Outcome

What your assumptions give, and the path from today's price.

Fair value

$3.11

Expected return

19.8% a year

Future price, 2031

$5.01

Buy below

$2.33

Price 35% below fair valuePrice $2.03, at your 10% return

Projection

Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.

Compugen (CGEN) intrinsic value and fair value

The calculator grows one of Compugen's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for CGEN; this is analysis, not investment advice.

Frequently asked

What is Compugen's (CGEN) intrinsic value?+

With Intrinsiqq's starting inputs, Compugen's fair value is about $3.11 a share, based on its earnings per share. That assumes earnings per share of $0.29 grows about 5.0% a year for 5 years, the stock then trades at 13.4 times earnings, and you want a 10.0% yearly return. On its other figures: free cash flow $1.32, revenue $6.95. Every input can be changed on the page; the result is a model, not a forecast.

Is Compugen overvalued?+

At $2.03, the price is 35% below that fair value of $3.11, and buying at today's price would return about 19.8% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from SEC filings, not investment advice.

What growth does the Compugen valuation assume?+

Earnings per share grows about 5.0% a year to start, a default, because there is too little history. The exit multiple starts at its industry's median.

What is a good margin of safety for Compugen?+

A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $2.33. Less predictable businesses deserve a wider cushion, or a higher desired return.

How the market compares: US profitability statistics

SourceFair value computed from the 10-K filed 2 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 7 Jun 2026. How this is calculated.

Price from market data, last close as of 4 Nov 2026. Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CGEN

CompareIntrinsic value
PLXProtalix Biotherapeutics Inc.
$2.69+3.07%68
RXRXRecursion Pharmaceuticals, Inc.
$3.88+5.43%25
MGTXMeiraGTx Holdings plc
$9.42-1.05%74
VIRVir Biotechnology Inc.
$11.77+4.90%10
CSBRChampions Oncology, Inc.
$4.83+0.00%26
RGNXRegenxbio Inc.
$7.71+1.05%40
FDMT4D Molecular Therapeutics, Inc.
$12.28+2.76%40
IVVDInvivyd Inc.
$0.63+8.93%10

Held by ETFs

CGEN is in 1 US ETF. The largest of them, with CGEN's weight in each:

Spot a number that looks wrong? Check it in CGEN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CGEN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.